Capital Markets Day 2023: New Mid-Term Guidance 2024 – 2028 Supported by Ramp-Up of Growth Projects
At its Capital Markets Day, Lonza outlined its Mid-Term Guidance for 2024 to 2028, including: 11–13% sales growth, 3…
Newsrooms
Vaxcyte and Lonza Expand Collaboration for Global Commercial Manufacturing of Broad-Spectrum Pneumococcal Conjugate Vaccines (PCVs)
. New agreement to establish global commercial manufacturing capacity for Vaxcyte's PCV candidates, VAX-24 and VAX-31,…
Lonza Announces New Filling Line for Commercial Supply of Antibody-Drug Conjugates for a Dedicated Customer
The new cGMP filling line at Lonza’s Stein (CH) site will enable handling and filling of bioconjugates for commercia…
Lonza Further Extends Collaboration with Major Biopharmaceutical Partner for Manufacturing Antibody-Drug Conjugates
Extended long-term collaboration to provide significant additional bioconjugation capacity for commercialization of…
KYAN Technologies, Alentis Therapeutics, and CELLphenomics Join Forces Combining Cutting-edge Optim.AI™ and PD3D® Models to Advance Claudin-1 Expression Research
KYAN Technologies, a vanguard combinatory drug development solutions provider, is thrilled to announce a strategic partn…
New Avantra 24 AIOps Platform Automates Handling of Security Notes, Certificates, and Enterprise Add ins
Avantra, the industry leading AIOps platform for SAP operations automation, announced the upcoming release of its Avantr…
Straumann Group acquires AlliedStar, an intraoral scanner provider in China
Straumann Group to acquire AlliedStar to complement its intraoral scanner portfolio across different price points and ex…
Lonza Confirms Details of Capital Markets Day and Reconfirms Outlook 2023
Capital Markets Day 2023 will be hosted by members of the Lonza Executive Committee The presentation will provide an ove…
Board Announcement
CEO Pierre-Alain Ruffieux to leave Lonza Albert M. Baehny to step in as CEO ad interim Capital Markets Day on October 17…
Straumann Group reports strong second-quarter result
Half-year revenue reached CHF 1.2 billion, growing 7.5% organically, achieving CHF 621 million or 11.7% in the second qu…